جستجوی مقالات مرتبط با کلیدواژه « nano-curcumin » در نشریات گروه « پزشکی »

Asthma is a common disease and curcumin has modest effect in inflammatory disorders. This study investigated the efficacy of nano-curcumin on asthma.

In this double-blinded randomized clinical trial, 60 patients with non-atopic bronchial asthma were randomly stratified in two groups of intervention (N=30) and control (N=30) groups. Apart from their standard treatment, the intervention group received 40 mg nano-curcumin (soft gel) three times daily while the control group received placebo. During the 60-day study, patients were assessed using spirometry to measure Forced expiratory volume in first second (FEV1). Asthma control test (ACT) was completed every 30 days and asthma quality of life questionnaire (AQLQ) was completed at the first and end of the study.

Totally, 31 patients (51.7%) were male and the mean age was 51.45±12.58 years. FEV1 was improved but there was no significant difference between intervention and control groups. ACT and AQLQ domains scores significantly improved. However, it was not statistically different between control and intervention groups.

Nano-curcumin at administered dosage had no additive effect on the standard treatment in asthmatic patients.

Pain and inflammation can be treated by various therapies that for the most part are not effective and can result in adverse effects. The current study was proposed to compare the antinociceptive and anti-inflammatory actions of curcumin and nano curcumin in rats.

Experimental approach:

 Rats were randomly allocated into ten groups of six for formalin and tail-flick tests including the control group, curcumin and nano curcumin groups (20, 50, 100 mg/kg), morphine group (10 mg/kg), naloxone + 100 mg/kg curcumin group, and naloxone + 100 mg/kg nano curcumin group. There were nine groups for the carrageenan test. Groups 1-7 were the same as the previous division; groups 8 and 9 received 10 mg/kg diclofenac and 1% carrageenan, respectively.

All doses of nano curcumin significantly decreased the paw-licking time in both phases of the formalin test. In the tail-flick test, curcumin 100, nano curcumin 100, naloxone + curcumin 100, and naloxone + nano curcumin 100 showed significant analgesic effects compared to the control group. In the paw edema test, at 180 s after injection, curcumin (50 and 100 mg/kg) and all doses of nano curcumin significantly inhibited carrageenan-induced edema. Myeloperoxidase activity and lipid peroxidation decreased at doses of 50 and 100 mg/kg of curcumin but at three doses of nano curcumin (20, 50, and 100 mg/kg).

Conclusion and implication:

 In conclusion, our results suggest that the nanoemulsion formulation of curcumin can be efficient in reducing pain and especially inflammation in lower doses compared to the native form of curcumin.

stement of the Problem: 

Due to the unfavorable properties of eugenol, the eugenol content can be reduced to improve the properties of zinc oxide eugenol (ZOE) by making a new combination of nanocurcumin called curcumin pulpal paste (CPP).

The aim of this in vitro study was to evaluate the solubility and tooth discoloration of three concentrations of CPP compared to ZOE, and Metapex.

In this in vitro study for evaluating of the solubility, five groups including ZOE, Metapex, and three concentrations of CPP (5%, 10%, and 20%) were tested. For evaluating the solubility, the changes in of the weight of samples were measured at 1, 3, 7 and 30 days after initial setting. In order to evaluate the tooth discoloration, 75 bovine maxillary anterior teeth were filled with one of five pulpal pastes. The changes in tooth color were evaluated at 1 hour, 1 week, 1 and 3 months after material placement.

The solubility increased by increasing the nano-curcumin percentage in CPPs. After 30 days, the solubility of the 5%CPP, and ZOE was not significantly different (p= 1.000). According to the colorimetric test, after 3 months, the highest discoloration was recorded for 20%CPP (8.45), and the smallest discoloration was registered for Metapex (4.06). The discoloration of 5%CPP, and 10% CPP was similar to ZOE’s color change (p> 0.05).

The results of the present study showed that the solubility of pulpal paste has increased with increasing curcumin concentrations. Therefore, pulpal paste with different nanocurcumin concentrations can be used considering the patient's age and the desired time of deciduous tooth loss, and dissolution of pulpal paste. Concerning the discoloration after 3 months, Metapex was the best material and the most discoloration rate was related to 20%CPP, and there was no difference between the 5% CPP, and 10% CPP with ZOE.

One of the most important neurotrophins is brain-derived neurotrophic factor (BDNF) that is closely associated with insulin resistance and Type 2 Diabetes Mellitus (T2DM). This study was done under the objective of investigating the effects of curcumin (CUR) and nano-curcumin (nCUR) on serum levels of BDNF, fasting blood sugar (FBS), water and food intake, and body weight in T2DM rats. 

Our work required the division of 48 male Wistar rats into the 6 groups of Control, diabetic, diabetic treated with two doses of CUR and nCUR (100 and 200 mg/kg), T2DM induced rats by intraperitoneal injection of Streptozotocin, and nicotinamide in the fasting state. Once the rats received nCUR and CUR doses through gavage for 28 days, their Serum level of BDNF was measured at the end of intervention period, while their body weight, FBS, and food and water intake were also examined at both onset and ending of this period.

Considering the effect of curcumin and nano-curcumin administration on the induced significant increase in serum BDNF and decrease in FBS, food, and water intake in T2DM rats (P<0.05), we can confirm the superior effectiveness of nano-curcumin 100 in serum BDNF elevation than curcumin (P<0.05). It is also notable that the body weight of intervention groups did not face any significant reduction when compared to that of diabetic control group.

These findings provide evidence for the beneficial effects of CUR and nCUR as an antidiabetic agent, which can be potentially considered as an adjunct for the available diabetes therapies.

This study aimed to investigate the effect of resistance training and nano-curcumin supplementation on matrix metallopeptidase 13 (MMP13) and cartilage oligomeric matrix protein (COMP) in patients with knee osteoarthritis.

In this open-label parallel randomized trial study 40 women aged between 45-60 years with knee osteoarthritis (OA) were randomly divided into the control, resistance training, nano-curcumin supplementation, and resistance training + nano curcumin supplementation groups. Socio-demographic characteristics, anthropometric and clinical parameters of the patients (WOMAC test) were collected at the beginning and end of the study. The levels of MMP 13 and COMP in the synovial fluid were measured with a human-specific ELISA kit.

Resistance training, supplement intake, and training/supplementation did not significantly change the synovial levels of COMP and MMP 13. Compared with the control group, WOMAC scores were significantly higher in the intervention groups (P = 0.038).

Resistance training and nano-curcumin by changing the WOMAC scores of patients with osteoarthritis can have a beneficial effect on improving the condition of these patients.

Traumatic brain injury (TBI) is one of the critical causes of death in trauma patients. In this study, the effect of nanocurcumin on the outcome of severe TBI was investigated for the first time in humans.

Methods and Materials/Patients:

 This randomized, double-blind, and paralleled controlled study included 128 patients aged from 18 to 70 years with severe brain trauma. Patients were randomly assigned to control group (standard care treatment+placebo) and intervention group (standard care treatment+oral nanocurcumin). Changes in the level of consciousness, cerebral edema, kidney function, liver enzymes, sodium and potassium electrolytes, and brain function were followed up and compared until 6 months after discharge.

The Mean±SD in the intervention (14.44±31.86 years) and control patients (14.86±33.34 years) had no significant difference (P=0.543). Both groups were similar in terms of gender (P=0.669). The average level of consciousness in the intervention group increased by about 3 units (P=0.004) and more than 2 units (P=0.002) at discharge compared with the control group. By comparing the optimal performance of patients in the first (P=0.389) trimester and second (P=0.309) trimester after discharge, no significant difference was observed between the intervention and control groups. The amount of brain edema caused by severe brain trauma on the seventh day of treatment in the intervention group was lower than that in the control group (P=0.038).

Administrating oral nanocurcumin supplement in patients with severe brain trauma along with their routine treatment is effective in improving brain edema and their level of consciousness without causing coagulation, and liver and kidney complications. These findings are not only statistically significant but also clinically vital.

Metabolic syndrome (MS) is a cluster of cardio-metabolic risk factors. MS is known as a highly prevalent disease worldwide. According to the existing evidence, consuming curcumin has positive effects on lipids profile, glucose, and body weight. This study aimed to evaluate the effects of nano-curcumin therapy on insulin resistance and serum level of afamin in patients with MS. Thirty MS patients (15 males and 15 females) received 80 mg/daily nano-curcumin for two months. The samples of fasting blood were collected from the participants at the beginning and 60 days after initiation of the intervention to measure biomarkers. Comparing pre- and post-treatment with nano-curcumin values revealed a significant decrease in fasting plasma glucose (FPG) (p=0.017), insulin, homeostatic model assessment of insulin resistance (HOMA-IR) (p=0.006), and afamin (p=0.047). Moreover, there was a significantly negative relationship between afamin and high-density lipoprotein cholesterol (HDL-C) (p=0.044), as well as a significantly positive relationship between afamin and systolic (SBP) (p <0.001) and diastolic (DBP) (p <0.001) blood pressures. Results suggest that taking nano-curcumin for 60 days may have positive effects on afamin, FPG, insulin, and HOMA-IR in patients with MS, but would not significantly affect other metabolic profiles. More studies with larger sample sizes are required to confirm these findings.

This study evaluated the effects of nano-curcumin intake on metabolic status in patients with diabetes on hemodialysis (HD).

This randomized, double-blind, placebo-controlled clinical trial was performed on 60 patients with diabetes on HD. Participants were randomly divided into two groups to take either 80 mg/d nano-curcumin (n = 30) or placebo (n = 30) for 12 weeks.

Nano-curcumin significantly decreased fasting plasma glucose (β = -19.68 mg/dL, 95% CI: -33.48 to -5.88; P < .05) and serum insulin levels (β = -1.70 µIU/mL, 95% CI: -2.96 to -0.44; P < .05) when compared with patients who received placebo. Nanocurcumin treatment was associated with a significant reduction in triglycerides (β = -16.13 mg/dL, 95% CI: -31.51 to -0.75; P < .05), VLDL-cholesterol (β = -3.22 mg/dL, 95% CI: -6.30 to -0.15; P < .05), total cholesterol (β = -17.83 mg/dL, 95% CI: -29.22 to -6.45; P < .05), LDL-cholesterol (β = -15.20 mg/dL, 95% CI: -25.53 to -4.87; P < .05), and total-cholesterol/HDL-cholesterol ratio (β = -1.15, 95% CI: -0.2.10 to -0.21; P < .05) when compared with the placebo. Nanocurcumin also resulted in a significant reduction of serum high sensitivity CRP (β = -0.78 mg/L, 95% CI: -1.41 to -0.15; P < .05), and plasma malondialdehyde (β = -0.25 µmol/L, 95% CI: -0.45 to -0.04; P < .05); but also with a significant increase in plasma total antioxidant capacity (β = 52.43 mmol/L; 95% CI: 4.52 to 100.35; P < .05) and total nitrite levels (β = 3.62 µmol/L, 95% CI: 2.17 to 5.08; P < .001) when compared with placebo.

Nano-curcumin intake for 12 weeks had beneficial effects on metabolic profile in patients with diabetes on HD.

Paraquat (PQ), as the most widely used herbicide in agriculture, induces poisoning in humans and animals mainly through oxidative stress. This study aimed to investigate the protective effects of nano-curcumin compared with curcumin against PQ-induced mitochondrial dysfunction.

Thirty-six Wistar rats were used in this study. They were separated into 6 groups: control subjects and animals poisoned with PQ that received treatment with or without curcumin and nano-curcumin for 7 days. Liver mitochondria were isolated, and oxidative stress markers, including Total Antioxidant Capacity (TAC), Lipid Peroxidation (LPO), Catalase (CAT) and Superoxide Dismutase (SOD) activity, as well as viability and mitochondrial membrane potential, were assessed.

Poisoning by PQ significantly increased the LPO levels and considerably decreased the TAC, CAT, and SOD activity compared with the control subjects (P<0.05). PQ-induced oxidative significantly damaged the viability and membrane potential of mitochondrial compared with controls (P<0.05). Administration of nano-curcumin significantly increased the SOD activity, as well as viability and mitochondrial membrane potential in the PQ group (P<0.05). Besides, treatment by nano-curcumin in the PQ group significantly improved the lipid peroxidation process (P<0.05).

Nanocurcumin is more effective than curcumin in reducing the PQ-induced oxidative damage

 Hemodialysis (HD) patients are considered as a high-risk population for cardiovascular disease, within which morbidity and mortality have been determined to be associated with dyslipidemia, pro-inflammatory cytokines, increased levels of C-reactive protein (CRP), and adhesion molecules (ICAM-1, VCAM-1). Different markers have been investigated to detect inflammation in hemodialysis patients, as well as the prognostic values of these markers.

The present study aimed to investigate the effect of nano-curcumin (120 mg) over 12 weeks on hs-CRP levels, adhesion molecules (ICAM-1, VCAM-1), and serum lipid profiles on hemodialysis patients in a randomized controlled clinical trial.

The results revealed that the mean serum hs-CRP level in the nano-curcumin group exhibited a decrease by the end of the study, when compared to mean serum hs-CRP level in the placebo group. However, this intra-group trend was not found to be statistically significant (P > .05). Nevertheless, a significant difference was determined between the values in the group receiving nano-curcumin, in comparison with the placebo group, at the end of the study (P < .001). Based on the attained results, mean serum levels of VCAM-1 in the nano-curcumin group were significantly reduced at the end of the study, compared with the placebo group (P < .001). Furthermore, the intra-group changes comparison showed significant reductions in serum levels of ICAM1 in patients treated with nano-curcumin at the end of the study (P < .05). Additionally, though decreases in mean triglycerides, total cholesterol, LDL-C were noted, there were no statistically significant intra-group differences (P > .05). Moreover, intra-group changes comparison of HDL-C levels and fasting blood sugar did not show any significant changes.

The current study indicates that nano-curcumin may show beneficial effects in lowering inflammation and hs-CRP levels, as well as adhesion molecules (ICAM-1, VCAM-1), in hemodialysis patients. However, the evidence is still insufficient.

Aluminum phosphide (AlP) is commonly used pesticide which could cause poisoning mainly through the induction of oxidative stress. The present study aimed to evaluate the effects of nano-curcumin and curcumin on the oxidant and antioxidant system in the liver mitochondria using AIP-induced toxicity model. In this study, 36 male albino Wistar rats were randomly divided into six groups (n=6). The control subjects and animals poisoned with AlP (2 mg/kg) received treatment with and without nano-curcumin (100 mg/kg) and curcumin (100 mg/kg) for seven days. Mitochondria were isolated from the liver and analyzed in terms of lipid peroxidation (LPO), total antioxidant capacity (TAC), total thiol groups (TTGs), superoxide dismutase (SOD), and catalase activity. In addition, mitochondrial viability was assessed. AlP caused a significant increase in the LPO levels, while significantly decreasing TAC, TTG, SOD, catalase activity, and mitochondrial viability compared to the controls (P<0.05). Moreover, nano-curcumin treatment significantly enhanced TAC, TTG, SOD, and mitochondrial viability (P<0.05). Curcumin could also improve TTG and mitochondrial viability (P<0.05). According to the results, nano-curcumin exerted protective effects against AlP-induced experimental toxicity, and the effect was attributed to the antioxidant properties of this compound.

Berberine and Nano-curcumin are two herbal medicines with strong anti-cancer effects on tumor cells, but low toxicity on normal cells, when used alone. Breast cancer is known as the most common cancer in women and second deadly one. In this study, we evaluated the cytotoxicity effects of combination Berberine and Nano-curcumin in breast cancer cell line to see whether they have further synergism cytotoxicity on MCF-7 breast cancer cell line.
The cytotoxicity effects of Berberine and Nano-curcumin alone and in combination, were evaluated in MCF-7 cell lines using MTT cytotoxicity test. Statistical analysis is done through one-way ANOVA and Tukey multiple range tests.
Analyzing results of this study showed that cytotoxicity of Nano-curcumin was higher than Berberine in a dose-dependent manner. The IC50 of combination Berberine and Nano-curcumin was lower and showed higher cytotoxicity in MCF-7 cells compared with the time we use each of these drugs alone.
In this study co-treatment of Berberine and Nano-curcumin significantly inhibited the growth of MCF-7 breast cancer cell line and resulted in synergism cytotoxicity effects. These results indicated on their potency to further combination of these two drugs with other agents and common chemotherapies to improve breast cancer outcomes.